Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 10/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920835 | 0.85 | ALDH1A1 (0.40) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL7531320 | 0.81 | KMT2A (0.43) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL1456261 | 0.79 | PTGS2 (0.46) | RAB9ANPC1POLBMAPTPTGS2 | |
| SCHEMBL6510845 | 0.79 | PTGS2 (0.46) | RAB9ANPC1POLBMAPTPTGS2 | |
| SCHEMBL20138424 | 0.78 | HDAC1 (0.43) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL11038097 | 0.71 | MEN1 (0.51) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL11324512 | 0.70 | ABCB1 (0.62) | L3MBTL1RAB9ANPC1MAPTATM | |
| SCHEMBL29021512 | 0.70 | MAPT (0.52) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL21530861 | 0.69 | MEN1 (0.66) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL21530862 | 0.69 | MEN1 (0.66) | MEN1KMT2AL3MBTL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003103593-A2 | SECRETASES RELATED TO ALZHEIMER'S DEMENTIA | BUCK INSTITUTE (US) | 2003-12-18 | — | — | WO | claimed |
| US-20020072050-A1 | Secretases related to Alzheimer's dementia | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-06-13 | — | — | US | claimed |
| EP-1121423-A2 | SECRETASES RELATED TO ALZHEIMER'S DEMENTIA | Hook, Vivian Y. H. (US) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023576-A2 | SECRETASES RELATED TO ALZHEIMER'S DEMENTIA | HOOK VIVIAN Y H (US) | 2000-04-27 | — | — | WO | claimed |
| EP-0695750-B1 | Naphthyridinium derivative, method for its production; antibody against said derivative and the use of said antibody | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-03-01 | — | — | EP | claimed |
| EP-0389437-B1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1995-05-24 | — | — | EP | claimed |
| US-5128069-A | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | claimed |
| US-20230087342-A1 | AZEPANE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-4001280-A1 | METHOD FOR PRODUCING PHENOL DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| EP-3984982-A1 | METHOD FOR PRODUCING MORPHINAN DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021132637-A1 | METHOD FOR PRODUCING CYCLIC SECONDARY AMINE | 日本ケミファ株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021015108-A1 | METHOD FOR PRODUCING MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2021-01-28 | — | — | WO | disclosed |
| WO-2021015109-A1 | METHOD FOR PRODUCING PHENOL DERIVATIVE | 日本ケミファ株式会社 | 2021-01-28 | — | — | WO | disclosed |
| US-4252715-A | SERINE PROTEASE, OLIGOPEPTIDE FOR DIAGNOSTIC DETERMINATION OF FACTOR XA | AB KABI (SE) | 1981-02-24 | — | — | US | disclosed |
| US-4214049-A | SPECTROPHOTOMETRIC ANALYSIS OF HYDROLYSIS PRODUCTS | AB KABI (SE) | 1980-07-22 | — | — | US | disclosed |
| US-4190574-A | CHROMOPHORE- OR FLUORESCENT-SUBSTITUTED OLIGOPEPTIDE | PENTAPHARM A.G. (CH) | 1980-02-26 | — | — | US | disclosed |
| US-4162941-A | CONTACTING WITH A PEPTIDE SUBSTRATE AND MEASURING THE ENZYMATIC HYDROLYSIS | AB KABI (SE) | 1979-07-31 | — | — | US | disclosed |
| US-4137225-A | SPECIFIC FOR SERINE PROTEASE, ENANTIOMORPHS | AB KABI (SE) | 1979-01-30 | — | — | US | disclosed |
| US-4028318-A | FOR SERINE PROTEASES | A B KABI (SW) | 1977-06-07 | — | — | US | disclosed |
| US-4016042-A | SYNTHETIC OLIGOPEPTIDE CONTAINING A CHROMOGENIC OR FLUORESCENT GROUP SPLIT OFF BY PROTEOLYTIC ENZYMES | PENTAPHARM A.G. (CH) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087342-A1 | AZEPANE DERIVATIVE | ADCY10, AZI2, PRMT1 | MEN1 319/4885KMT2A 2582/4885L3MBTL1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.